All In Biotech

NDA 020630 · Mylan Institutional

Ultiva

Remifentanil Hydrochloride · Injection

Novel

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Jul 12, 1996

Approved uses

4

Original approval plus efficacy supplements

Registered trials

814

54 Phase 3, 47 recruiting

FAERS reports

2,419

2,326 serious, 247 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF ULTIVA Addiction, Abuse, and Misuse Because the use of ULTIVA exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient’s risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions [see Warnings and Precautions (5.1) ] . Life-Threatening Respiratory Depression Serious, life-threatening, or fatal respiratory depression may occur with use of ULTIVA, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of ULTIVA are essential [see Warnings and Precautions (5.2) ] . Risks From Concomitant Use With Benzodiazepines Or Other CNS Depressants Concomitant use of opioids with benzodiazepines or other central nervous...

What it is approved for

From the label in effect Dec 15, 2025.

ULTIVA is indicated for intravenous (IV) administration: • As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. • For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting. • As an analgesic component of monitored anesthesia care in adult patients. ULTIVA is an opioid agonist indicated for intravenous administration: • As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. ( 1 ) • For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting. ( 1 ) • As an analgesic component of monitored anesthesia care in adult patients. ( 1 )

Mechanism: ULTIVA is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of ULTIVA is antagonized by opioid antagonists, including overdose reversal agents such as naloxone or nalmefene. Unlike other opioids, ULTIVA is rapidly metabolized by hydrolysis of the propanoic acid-methyl ester linkage by nonspecific blood and tissue esterases. ULTIVA is not a substrate for plasma cholinesterase (pseudocholinesterase) and, therefore, patients with atypical cholinesterase are expected to have a normal duration of action.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 8, 2004 Supplement 5 · Efficacy LabelLetter
  • Nov 23, 1999 Supplement 2 · Efficacy
  • Oct 15, 1999 Supplement 1 · Efficacy
  • Jul 12, 1996 Original approval · Type 1 - New Molecular Entity Review
3 products under this application
  • ULTIVA · REMIFENTANIL HYDROCHLORIDE EQ 5MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • ULTIVA · REMIFENTANIL HYDROCHLORIDE EQ 1MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
  • ULTIVA · REMIFENTANIL HYDROCHLORIDE EQ 2MG BASE/VIAL · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Remifentanil" as an intervention, any sponsor and status, largest first.

All 814 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • anaphylactic shock370
  • hypotension166
  • anaphylactic reaction151
  • cardiac arrest122
  • blood pressure decreased105
  • bradycardia88
  • tachycardia87
  • bronchospasm78
  • rash72
  • erythema63
  • toxic epidermal necrolysis62
  • drug ineffective59

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200426
200541
200624
200743
200867
200980
2010104
201190
2012128
2013166
2014129
2015109
2016144
201795
2018155
2019125
2020111
202198
2022151
2023149
2024126
2025131
2026126

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • Current · updated Nov 18, 2026

    Ultiva, Injection, 1 mg/1 mL (NDC 72078-034-01).

  • Current · updated Nov 18, 2026

    Ultiva, Injection, 2 mg (NDC 72078-035-02).

  • Current · updated Nov 18, 2026

    Ultiva, Injection, 5 mg (NDC 72078-036-05).

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,608 on PubMed

Sponsor: Mylan Institutional

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.